» Articles » PMID: 36191832

Osteoarthritis Bone Marrow Lesions

Overview
Date 2022 Oct 3
PMID 36191832
Authors
Affiliations
Soon will be listed here.
Abstract

Assessment and treatment of Bone Marrow Lesions (BMLs) could ultimately make step changes to the lives of people with osteoarthritis (OA). We here review the imaging and pathological characteristics of OA-BMLs, their differential diagnosis and measurement, and cross-sectional and longitudinal associations with pain and OA structural progression. We discuss how biomechanical and cellular factors may contribute to BML pathogenesis, and how pharmacological and non-pharmacological interventions that target BMLs might reduce pain and OA structural progression. We critically appraise semiquantitative and quantitative methods for assessing BMLs, and their potential utilities for identifying people at risk of symptomatic and structural OA progression, and evaluating treatment responses. New interventions that target OA-BMLs should both confirm their importance, and reduce the unacceptable burden of OA.

Citing Articles

Ghrelin suppresses apoptosis and autophagy in osteoarthritis synovial cells by modulating the ADORA2B/PI3K/Akt/mTOR signaling pathway.

Ye N, Huang J, Zhang Y, Yang Y J Orthop. 2025; 68:27-33.

PMID: 39995546 PMC: 11846923. DOI: 10.1016/j.jor.2025.01.029.


Statin use and longitudinal bone marrow lesion burden: analysis of knees without osteoarthritis from the Osteoarthritis Initiative study.

Moradi K, Mohajer B, Guermazi A, Hadidchi R, Mohammadi S, Cao X Skeletal Radiol. 2025; .

PMID: 39890641 DOI: 10.1007/s00256-025-04878-6.


Mapping the knowledge landscape: A bibliometric analysis of exosome research in osteoarthritis (2004-2023).

Xu H, Wang Z, Wang Z, Chen J, Zhao C, Kang B Heliyon. 2024; 10(23):e40079.

PMID: 39717577 PMC: 11665376. DOI: 10.1016/j.heliyon.2024.e40079.


The rat osteoarthritis bone score for histological pathology relevant to human bone marrow lesions and pain.

McWilliams D, Shahtaheri M, Koushesh S, Joseph C, Gowler P, Xu L Osteoarthr Cartil Open. 2024; 7(1):100544.

PMID: 39717525 PMC: 11665527. DOI: 10.1016/j.ocarto.2024.100544.


EUROVISCO Consensus Guidelines for the Use of Hyaluronic Acid Viscosupplementation in Knee Osteoarthritis Based on Patient Characteristics.

Conrozier T, Raman R, Diracoglu D, Montfort J, Bard H, Baron D Cartilage. 2024; :19476035241271970.

PMID: 39564753 PMC: 11577334. DOI: 10.1177/19476035241271970.